Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Advisory Committee Schedule Hints At Re-formulated Compounding Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency has not set a meeting date for the Pharmacy Compounding Drugs Advisory Committee, defunct since 2002, in its tentative schedule, but has included 13 vacancies on the panel in its list of committees in need of new members.

You may also be interested in...

FDA Bulk Compounding Substance Review: Task For Advisory Committee – Or Sisyphus?

Six nominees for the compounding bulk drug substances list will be discussed during the first Pharmacy Compounding Advisory Committee Meeting since its restart, but trade group proposed more than 1,500 for review.

FDA Compounding Advisory Panel Re-formed With Many Pending Issues

Fourteen committee members could give advice on Good Manufacturing Practices for registered outsourcing facilities as well as help determine list of drugs that cannot be compounded.

Compounding: Hamburg Asks Purchasers, States To Push Outsourcer Registration

Letters seek help encouraging large-scale compounders to register with the agency as outsourcing facilities; FDA also seeks nominations for its compounding advisory committee.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts